keyword
MENU ▼
Read by QxMD icon Read
search

Antiemetics

keyword
https://www.readbyqxmd.com/read/29790666/rolapitant-for-the-prevention-of-nausea-in-patients-receiving-highly-or-moderately-emetogenic-chemotherapy
#1
Rudolph M Navari, Bernardo L Rapoport, Dan Powers, Sujata Arora, Rebecca Clark-Snow
Most patients receiving highly or moderately emetogenic chemotherapy experience chemotherapy-induced nausea and vomiting without antiemetic prophylaxis. While neurokinin-1 receptor antagonists (NK-1RAs) effectively prevent emesis, their ability to prevent nausea has not been established. We evaluated the efficacy of the long-acting NK-1RA rolapitant in preventing chemotherapy-induced nausea using post hoc analyses of data from 3 phase 3 trials. Patients were randomized to receive 180 mg oral rolapitant or placebo approximately 1-2 hours before chemotherapy in combination with a 5-hydroxytryptamine type 3 RA and dexamethasone...
May 23, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29788744/general-practitioners-participation-in-cancer-treatment-in-norway
#2
Knut Holtedahl, Benedicte I Scheel, May-Lill Johansen
INTRODUCTION: General practitioners (GPs) participate in a patient's cancer care to different extents at different times, from prevention and diagnosis to treatment and end-of-life care. Traditionally, the GP has had a minor role in cancer treatment. However, oncological and surgical services frequently delegate limited cancer treatment tasks to GPs, especially in rural areas far from hospitals. The aim of this study was to explore the extent of GPs' participation in cancer treatment in Norway...
May 2018: Rural and Remote Health
https://www.readbyqxmd.com/read/29781466/antiemetic-guidelines-using-education-to-improve-adherence-and-reduce-incidence-of-cinv-in-patients-receiving-highly-emetogenic-chemotherapy
#3
Corrine Mellin, Mallory Lexa, Ashley Leak Bryant, Susie Mason, Deborah K Mayer
BACKGROUND: With the development of increasingly effective antiemetic regimens, guideline adherence can prevent 70%-80% of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer. OBJECTIVES: This quality improvement project aims to increase rates of adherence to national guidelines and, ultimately, decrease rates of CINV experienced by patients receiving highly emetogenic chemotherapy. METHODS: A retrospective chart analysis was performed...
June 1, 2018: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29764184/efficacy-of-the-combination-neurokinin-1-receptor-antagonist-palonosetron-and-dexamethasone-compared-to-others-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#4
Ronald Chow, May Tsao, Leonard Chiu, Marko Popovic, Milica Milakovic, Henry Lam, Carlo DeAngelis
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV), a common side effect of chemotherapy, can substantially impair a patient's quality of life, interfere with a patient's compliance with anticancer therapy, and result in the manifestation of adverse events such as electrolyte imbalance, dehydration and malnutrition. The most recent guidelines published by the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) recommend the combination of dexamethasone (DEX), a 5-hydroxytrypatmine-3 receptor antagonist (5-HT3RA), preferably palonosetron (PALO), and a neurokinin-1 receptor antagonist (NK1RA) for prophylactic treatment of CINV in patients receiving highly emetogenic chemotherapy (HEC)...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29764183/a-pilot-study-with-palonosetron-in-the-prophylaxis-of-radiation-induced-nausea-and-vomiting
#5
Vithusha Ganesh, Leah Drost, Carlo DeAngelis, Bo Angela Wan, Mark Pasetka, Stephanie Chan, Liying Zhang, May Tsao, Elizabeth Barnes, Natalie Pulenzas, Hans Chung, Pearl Zaki, Caitlin Yee, Edward Chow
BACKGROUND: Palonosetron is an effective antiemetic in chemotherapy-induced nausea and vomiting (CINV), but has yet to be studied in the radiation setting. The purpose of the present study was to investigate the efficacy and safety of palonosetron in the prophylaxis of radiation-induced nausea and vomiting (RINV). METHODS: Patients without existing nausea and vomiting undergoing palliative radiotherapy to sites with emetic risk were prescribed palonosetron 0.5 mg orally before the start of radiation treatment, and every other day until completion of treatment...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29758039/effects-of-palonosetron-for-prophylaxis-of-postoperative-nausea-and-vomiting-in-high-risk-patients-undergoing-total-knee-arthroplasty-a-prospective-randomized-double-blind-placebo-controlled-study
#6
Jung-Hee Ryu, Young-Tae Jeon, Byunghun Min, Jin-Young Hwang, Hye-Min Sohn
BACKGROUND: The preemptive multimodal pain protocols used in total knee arthroplasty (TKA) often cause emesis postoperatively. We investigated whether palonosetron prophylaxis reduces postoperative nausea and vomiting (PONV) in high-risk patients after TKA. METHODS: We randomized 120 female patients undergoing TKA to receive either palonosetron (0.075 mg, intravenous) or no antiemetic prophylaxis (0.9% saline, control group). All patients were given spinal anesthesia, a continuous femoral nerve block, and fentanyl-based intravenous patient controlled analgesia...
2018: PloS One
https://www.readbyqxmd.com/read/29756062/effect-of-preoperative-gabapentin-and-acetaminophen-on-opioid-consumption-in-video-assisted-thoracoscopic-surgery-a-retrospective-study
#7
Robert Qiu, Albert C Perrino, Holly Zurich, Nitin Sukumar, Feng Dai, Wanda Popescu
Background: Patients undergoing video-assisted thoracoscopic surgery (VATS) are particularly vulnerable to opioid-induced sedation and hypoventilation. Accordingly, reducing opioid consumption in these patients is a primary goal of multimodal analgesic regimens. Although administration of preoperative gabapentin and acetaminophen has been shown to decrease postoperative opioid consumption in other surgeries, this approach has not been studied in VATS lobectomy. Our objective was to examine the impact of the addition of preoperative gabapentin and acetaminophen to a VATS lobectomy multimodal analgesic plan on postoperative opioid consumption, nausea/vomiting, and sedation...
April 2018: Romanian Journal of Anaesthesia and Intensive Care
https://www.readbyqxmd.com/read/29744791/olanzapine-as-antiemetic-drug-in-oncology-a-retrospective-study-in-non-responders-to-standard-antiemetic-therapy
#8
Florian Slimano, Florence Netzer, Isabelle Borget, François Lemare, Benjamin Besse
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not been well defined. Objective To investigate the effectiveness of the addition of olanzapine to a standard triplet therapy for the prevention of CINV in patients who experienced CINV during their first chemotherapy course, despite receiving a well-managed prevention protocol. Setting One comprehensive cancer centre in France...
May 9, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29740979/otoplasty-techniques-in-children-a-comparative-study-of-outcomes
#9
Puvesh Punj, Hsu Phie Chong, Thomas P Cundy, Michelle Lodge, Roger Woods
BACKGROUND: Numerous otoplasty techniques have been described in the literature to correct prominent ears; however, few have focused on the complication rates. We reviewed our experience aiming to assess peri-operative care requirements and complication rates. METHOD: We conducted a retrospective review of 207 otoplasty procedures performed in 119 patients over a 5-year period (2009-2014) at the Women's and Children's Hospital, Adelaide. Information pertaining to demographic details, length of stay, otoplasty technique and complications (early and late) were obtained...
May 8, 2018: ANZ Journal of Surgery
https://www.readbyqxmd.com/read/29724299/comparison-of-antiemetic-effects-of-granisetron-and-palonosetron-in-patients-receiving-bendamustine-based-chemotherapy
#10
M Uchida, T Nakamura, Y Makihara, K Suetsugu, H Ikesue, Y Mori, K Kato, M Shiratsuchi, K Hosohata, T Miyamoto, K Akashi
The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29722791/phase-3-safety-study-of-intravenous-nepa-a-novel-fixed-antiemetic-combination-of-fosnetupitant-and-palonosetron-in-patients-receiving-highly-emetogenic-chemotherapy
#11
L Schwartzberg, E Roeland, Z Andric, D Kowalski, J Radic, D Voisin, G Rizzi, R Navari, R J Gralla, Meinolf Karthaus
Background: NEPA, an oral fixed combination of the NK1RA netupitant (300mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50mg), is the first fixed antiemetic combination to have been approved. A single oral NEPA capsule plus dexamethasone (DEX) given prior to AC and non-AC highly emetogenic chemotherapy (HEC) showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) over PALO plus DEX for 5 days post-chemotherapy. The safety of NEPA was well-established in the Phase 2/3 clinical program in 1169 NEPA-treated patients...
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29720113/a-randomized-open-label-study-of-guideline-driven-antiemetic-therapy-versus-single-agent-antiemetic-therapy-in-patients-with-advanced-cancer-and-nausea-not-related-to-anticancer-treatment
#12
Janet Hardy, Helen Skerman, Paul Glare, Jennifer Philip, Peter Hudson, Geoffrey Mitchell, Peter Martin, Odette Spruyt, David Currow, Patsy Yates
BACKGROUND: Nausea/vomiting (N/V) not related to anti-cancer treatment is common in patients with advanced cancer. The standard approach to management is to define a dominant cause, and treat with an antiemetic selected through pathophysiologic knowledge of emetic pathways. High rates of N/V control have been reported using both etiology-based guideline-driven antiemetic regimens and an empiric approach using single agents in uncontrolled studies. These different approaches had never been formally compared...
May 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29714004/non-bleeding-adverse-events-with-the-use-of-direct-oral-anticoagulants-a-sequence-symmetry-analysis
#13
Géric Maura, Cécile Billionnet, Joël Coste, Alain Weill, Anke Neumann, Antoine Pariente
INTRODUCTION: Postmarketing pharmacovigilance reports have raised concerns about non-bleeding adverse events associated with direct oral anticoagulants (DOACs), but only limited results are available from large claims databases. OBJECTIVE: The aim of this study was to assess the potential association between DOAC initiation and the onset of four types of non-bleeding adverse events by sequence symmetry analysis (SSA). METHODS: SSA was performed using nationwide data from the French National Healthcare databases (Régime Général, 50 million beneficiaries) to assess a cohort of 386,081 DOAC new users for the first occurrence of four types of non-bleeding outcomes: renal, hepatic, skin outcomes identified by using hospitalization discharge diagnoses, and gastrointestinal outcomes by using medication reimbursement...
April 30, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29707040/incidence-and-mitigation-of-gastrointestinal-events-in-patients-with-relapsing-remitting-multiple-sclerosis-receiving-delayed-release-dimethyl-fumarate-a-german-phase-iv-study-tolerate
#14
Ralf Gold, Eugen Schlegel, Birte Elias-Hamp, Christian Albert, Stephan Schmidt, Björn Tackenberg, James Xiao, Tom Schaak, Hans Christian Salmen
Background: Gastrointestinal (GI) events are common adverse events (AEs) associated with delayed-release dimethyl fumarate (DMF), an approved treatment for relapsing-remitting multiple sclerosis (RRMS). The objective of the TOLERATE study was to evaluate GI tolerability and GI mitigation via symptomatic therapies in patients initiating DMF in a real-world clinical setting in Germany. Methods: TOLERATE was a multicentre, open-label, single-arm study performed at 25 German sites...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29705919/retraction-note-to-combination-antiemetic-regimens-for-prevention-of-postoperative-nausea-and-vomiting-focus-on-high-risk-patients
#15
Yoshitaka Fujii
The Editor-in-Chief has retracted the original article [1] because a number of studies [2-15] included in this review (cited as references 25-29, 31, 32, 47, 48, 50-54) have been retracted, specifically those included in table III, table IV, section 3 and section 4.2. This has rendered the content of the review scientifically unreliable.
May 2018: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29702501/the-latest-consensus-on-antiemetics
#16
Jørn Herrstedt
PURPOSE OF REVIEW: The present review summarizes and discuss the most recent updated antiemetic consensus. RECENT FINDINGS: Two new neurokinin (NK)1-receptor antagonists, netupitant and rolapitant, have been approved by the Food and Drug Administration and the European Medicines Agency and incorporated in the latest versions of the MASCC/ESMO, ASCO, and NCCN guidelines. Guidelines all recommend a combination of a serotonin (5-HT)3-receptor antagonist, dexametha-sone, and a NK1-receptor antagonist in patients receiving highly emetogenic chemotherapy (HEC) with the addition of the multireceptor targeting agent, olanzapine, as an option in cisplatin or anthracycline-cyclophosphamide chemotherapy...
April 26, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29698275/reports-of-anaphylaxis-with-an-antiemetic
#17
Diane S Aschenbrenner
No abstract text is available yet for this article.
May 2018: American Journal of Nursing
https://www.readbyqxmd.com/read/29694459/characterizing-hospitalizations-for-pediatric-concussion-and-trends-in-care
#18
Tara Rhine, Terri Byczkowski, Mekibib Altaye, Shari L Wade, Lynn Babcock
BACKGROUND: Children hospitalized for concussion may be at a higher risk for persistent symptoms, but little is known about this subset of children. OBJECTIVE: Delineate a cohort of children admitted for concussion, describe care practices received, examine factors associated with prolonged length of stay (LOS) or emergency department (ED) readmission, and investigate changes in care over time. DESIGN, SETTING: Retrospective analysis of data submitted by 40 pediatric hospitals to the Pediatric Health Information System...
April 25, 2018: Journal of Hospital Medicine: An Official Publication of the Society of Hospital Medicine
https://www.readbyqxmd.com/read/29691180/multimodal-clinical-pathway-with-adductor-canal-block-decreases-hospital-length-of-stay-improves-pain-control-and-reduces-opioid-consumption-in-total-knee-arthroplasty-patients-a-retrospective-review
#19
Terry A Ellis, Hassan Hammoud, Philip Dela Merced, Nishankkumar P Nooli, Farhad Ghoddoussi, Joshua Kong, Sandeep H Krishnan
BACKGROUND: Total knee arthroplasty volume is increasing significantly in the United States. Reducing hospital length of stay may represent the best method for accommodating expanding volume and reducing costs. We hypothesized that tailoring a clinical pathway to facilitate early ambulation would decrease costs and resource utilization. METHODS: We conducted a sequential before-and-after study of total knee arthroplasty patients after a phased implementation of a clinical pathway that includes multimodal oral analgesic protocols, adductor canal nerve block, and standardized day of surgery ambulation protocols...
March 27, 2018: Journal of Arthroplasty
https://www.readbyqxmd.com/read/29690798/acute-chemotherapy-induced-nausea-and-vomiting-in-children-with-cancer-still-waiting-for-a-common-consensus-on-treatment
#20
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Paola Coccia, Silvia Triarico, Giorgio Attiná
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common treatment side-effects, and remains a significant concern, in children undergoing chemotherapy. Although adult patients receive chemotherapy regimens combined with appropriate standardized antiemetic treatment, children can receive markedly varying antiemetic treatments. A narrative review of CINV was performed regarding CINV definition, scoring system, prevention and treatment, specifically focussing on studies conducted with paediatric oncology patients...
January 1, 2018: Journal of International Medical Research
keyword
keyword
79588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"